Azitra (AZTR) Cash from Financing Activities (2022 - 2026)
Azitra's (AZTR) quarterly Cash from Financing Activities came in at $10.5 million in Q1 2026, up 501.42% YoY from $1.7 million in Q1 2025, and up 188.18% on a QoQ basis from $3.6 million in Q4 2025.
Azitra (AZTR) Cash from Financing Activities (2022 - 2026) Analysis & Trends
Azitra (AZTR) has 5 years of Cash from Financing Activities data on file, last reported at $10.5 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 501.42% year-over-year to $10.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.7 million (up 64.23% YoY) and the FY2025 annual result came in at $8.9 million, down 33.04% from the prior year.
- Cash from Financing Activities climbed to $10.5 million in Q1 2026, from $3.6 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $10.5 million in Q1 2026 to a low of -$272080.0 in Q1 2023.
- A 5-year average of $2.9 million and a median of $1.7 million in 2025 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 402621.1% in 2024, down 100.34% in 2024.
- Tracing AZTR's Cash from Financing Activities over 5 years: stood at -$176183.0 in 2022, then surged by 97.08% to -$5146.0 in 2023, then increased by 26.51% to -$3782.0 in 2024, then surged by 96416.08% to $3.6 million in 2025, then surged by 188.18% to $10.5 million in 2026.
- The last three Cash from Financing Activities figures came in at $10.5 million (Q1 2026), $3.6 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Azitra | 2.53 Mn | 2.53 Mn | - | 85,482.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 85,482.00 |
| Jun 30, 2026 | 85,482.00 |
| Mar 31, 2026 | 10.50 Mn |
| Mar 31, 2026 | 10.50 Mn |
| Dec 31, 2025 | 3.64 Mn |
| Dec 31, 2025 | 3.64 Mn |
| Sep 30, 2025 | 2.84 Mn |
| Sep 30, 2025 | 2.84 Mn |
| Jun 30, 2025 | 690,343.00 |
| Jun 30, 2025 | 690,343.00 |
| Mar 31, 2025 | 1.75 Mn |
| Mar 31, 2025 | 1.75 Mn |
| Dec 31, 2024 | -3,782.00 |
| Dec 31, 2024 | -3,782.00 |
| Sep 30, 2024 | 9.04 Mn |
| Sep 30, 2024 | 9.04 Mn |
| Jun 30, 2024 | -21,381.00 |
| Jun 30, 2024 | -21,381.00 |
| Mar 31, 2024 | 4.31 Mn |
| Mar 31, 2024 | 4.31 Mn |